Home LiteratureArticle Details
PMID: 8281874 Published · ppublish English Clinical Trial Comparative Study Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Effects of ranitidine 150 mg four times a day on 24-hour intragastric acidity and 24-hour plasma gastrin concentration.

Digestive diseases and sciences ·Vol. 39 ·No. 1 ·1994-01-00 ·Pages 91-6

Fraser AG, Sawyerr AM, Hudson M, Smith M, Pounder RE

Abstract

Twenty-four-hour integrated intragastric acidity and 24-hr integrated plasma gastrin concentration was measured twice in 23 healthy male volunteers on the seventh day of oral dosing with placebo or ranitidine 150 mg four times a day. The study was a randomized, double-blind, placebo-controlled, two-way crossover investigation. The mean integrated 24-hr intragastric acidity during dosing with ranitidine 150 mg four times a day decreased to 32% of the placebo value (placebo 825 mmol/hr/liter; ranitidine 265 mmol/hr/liter). The mean integrated 24-hr plasma gastrin concentration during dosing with ranitidine 150 mg four times a day was 904 pmol/hr/liter compared with placebo (410 pmol/hr/liter)--an increase of 122%. The median number of hours of pH > 3 during dosing with placebo and with ranitidine 150 mg four times a day were 5 and 11 hr, respectively. Ranitidine 150 mg four times a day caused a significant decrease of mean integrated intragastric acidity for each meal-related interval and also during the night.

MeSH Terms
Adult Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Esophagitis, Peptic/drug therapy Gastric Acid/metabolism Gastric Acidity Determination Gastrins/blood Humans Male Ranitidine/administration & dosage,pharmacology
Chemicals
Gastrins Ranitidine
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Fraser A G
University Department of Medicine, Royal Free Hospital School of Medicine, London, UK.
Sawyerr A M
Hudson M
Smith M
Pounder R E
References (13)
13 references, click to expand
  1. Rationale for high-dose H2-receptor blockade in the treatment of gastro-oesophageal reflux disease.
    Aliment Pharmacol Ther. 1991;5 Suppl 1:59-67 PMID: 1679673
  2. Effects of ranitidine, given t.d.s., on intragastric and oesophageal pH in patients with gastrooesophageal reflux.
    Aliment Pharmacol Ther. 1991 Dec;5(6):621-30 PMID: 1782305
  3. Tolerance during 5 months of dosing with ranitidine, 150 mg nightly: a placebo-controlled, double-blind study.
    Gastroenterology. 1991 Oct;101(4):948-53 PMID: 1889719
  4. Twenty-four-hour intragastric acidity in duodenal ulcer patients during dosing with placebo, and 150 mg ranitidine twice or four times daily.
    Aliment Pharmacol Ther. 1989 Jun;3(3):253-8 PMID: 2520620
  5. Royal Free Hospital protocol for 24-hour intragastric acidity and plasma gastrin concentration.
    Dig Dis. 1990;8 Suppl 1:10-7 PMID: 2225513
  6. Acute treatment of reflux oesophagitis: a multicentre trial to compare 150 mg ranitidine b.d. with 300 mg ranitidine q.d.s.
    Aliment Pharmacol Ther. 1989 Jun;3(3):259-66 PMID: 2520621
  7. A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis.
    Gastroenterology. 1991 Nov;101(5):1149-58 PMID: 1936784
  8. Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole.
    Aliment Pharmacol Ther. 1987 Jun;1(3):239-51 PMID: 2979226
  9. Basal acid output and gastric acid hypersecretion in gastroesophageal reflux disease. Correlation with ranitidine therapy.
    Dig Dis Sci. 1994 Feb;39(2):410-7 PMID: 8313826
  10. Drug-induced changes of plasma gastrin concentration.
    Gastroenterol Clin North Am. 1990 Mar;19(1):141-53 PMID: 2184125
  11. Gastric acid hypersecretion in refractory gastroesophageal reflux disease.
    Gastroenterology. 1990 Mar;98(3):654-61 PMID: 2298369
  12. Ranitidine in the treatment of duodenal ulcer disease: relationship between antisecretory effect and ulcer healing rate.
    Aliment Pharmacol Ther. 1991 Jun;5(3):227-43 PMID: 1888823
  13. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine.
    Aliment Pharmacol Ther. 1990;4 Suppl 1:29-45 PMID: 1983345
Article Info
Journal
Digestive diseases and sciences
Abbr.
Dig Dis Sci
ISSN
0163-2116
Published
1994-01-00
Pages
91-6
Language
English
Region
United States
NLM ID
7902782
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com